Suchergebnisse

Objectives:Many Asian Americans tend to report receiving lower quality services from direct service providers. Improving the cultural competence of social workers and other professionals who work with Asian Americans may address this dissatisfaction. To date, there are few tools to help educators and supervisors evaluate the level of cultural competence of social workers and other health professionals. This study reports on the development and testing of a cultural competence measure to evaluate social workers' preparedness for working with Asian American clients.Method:Based on a sample of 294 student social workers, the final 29-item instrument is a reliable and valid tool.Results:The instrument shows strong content validity according to expert panelists, robust reliability, excellent model fit, and preliminary evidence of construct validity.Conclusion:The validated Cultural Competency with Asian American Clients Scale could be used by social work educators in planning courses and assessing student readiness for work with Asian Americans.

BACKGROUND: COVID-19 has spread rapidly: from the first case in Dec 2019, the declaration of a global pandemic in Mar 2020, to Jun 18, 2020 with >8 M confirmed cases and >400,000 deaths worldwide. Throughout this rapid spread, Gilead has focused on contributing antiviral expertise and resources to help patients (pts) and communities fighting COVID-19 METHODS: Gilead is supporting the efforts of governments, partnering with professionals, and community-based org., and collaborating with healthcare providers to accelerate research and access to remdesivir (RDV), the first medicine with demonstrated efficacy in treatment of COVID-19. This is a review of the programs initiated in RDV research, access, research grants and collaborative education RESULTS: In Jan 2020 Gilead began working with government and regulatory authorities to make RDV accessible to pts globally through the compassionate use and expanded access programs. These programs has treated >2000 COVID-19 pts. By Feb 2020, several phase 3 randomized trials on RDV were initiated. Based on trials completed and published data (n= >2000), RDV was granted emergency use authorization in the US on May 1, 2020 with full approval in 5 countries thereafter and several under review elsewhere. Collectively there will be >12,000 pts enrolled in RDV clinical programs by Dec 2020. Increasing manufacturing of RDV began at-risk in Jan 2020. By May 2020 Gilead has decreased production time, increased supply and committed to donating all its 1.5 M doses. Under the licensing agreements with generic drug manufacturers, RDV will be available in 127 countries upon approval. Gilead has committed to supporting research grants to enhance the understanding of the clinical course and outcomes in vulnerable population, long-term sequelae, and evaluate real world safety and effectiveness of COVID-19 therapies. Finally, Gilead has provided corporate grants to support the efforts of community-based orgs and public health entities to expand education on COVID-19 ...